Discordant association of C-reactive protein with clinical events and coronary luminal narrowing in postmenopausal women: Data from the women's angiographic vitamin and estrogen (WAVE) study

Clinical Cardiology

Volumn 36, Issue 9, 2013, Pages 535-541

  Patel, Dhavalkumar ^a,b   Jhamnani, Sunny ^a   Ahmad, Soha ^a   Silverman, Angela ^c   Lindsay, Joseph ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DISEASE PROGRESSION; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; RETROSPECTIVE STUDIES; VITAMINS;

EID: 84883881628     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22155     Document Type: Article

References (36)

1. Ross R., Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
2. Libby P, Ridker PM, Maseri A,. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-1143.
3. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151: 483-495.
4. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836-843.
5. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557-1565.
6. Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004; 25: 401-408.
7. Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004; 110: 1747-1753.
8. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002; 105: 2019-2023.
9. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol. 2005; 45: 1594-1599.
10. Lombardo A, Biasucci LM, Lanza GA, et al. Inflammation as a possible link between coronary and carotid plaque instability. Circulation. 2004; 109: 3158-3163.
11. Hsia J, Alderman EL, Verter JI, et al. Women's angiographic vitamin and estrogen trial: design and methods. Control Clin Trials. 2002; 23: 708-727.
12. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002; 288: 2432-2440.
13. Oh J, Teoh H, Leiter LA,. Should C-reactive protein be a target of therapy? Diabetes Care. 2011; 34 (suppl 2): S155-S160.
14. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106: 913-919.
15. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039-1051.
16. Marnell L, Mold C, Du Clos TW,. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005; 117: 104-111.
17. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004; 109: 647-655.
18. Teoh H, Quan A, Lovren F, et al. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. 2008; 201: 318-325.
19. Zwaka TP, Hombach V, Torzewski J,. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001; 103: 1194-1197.
20. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009; 302: 37-48.
21. Grammer TB, Marz W, Renner W, et al. C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study. Eur Heart J. 2009; 30: 170-182.
22. Skowasch D, Jabs A, Andrie R, et al. Progression of native coronary plaques and in-stent restenosis are associated and predicted by increased pre-procedural C reactive protein. Heart. 2005; 91: 535-536.
23. Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: the Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol. 2002; 40: 1375-1382.
24. Nakachi T, Kosuge M, Hibi K, et al. C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ J. 2008; 72: 1953-1959.
25. Nicholls SJ, Tuzcu EM, Crowe T, et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol. 2006; 47: 1967-1975.
26. Bayturan O, Kapadia S, Nicholls SJ, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010; 55: 2736-2742.
27. Sander D, Schulze-Horn C, Bickel H, et al. Combined effects of hemoglobin a1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE Study. Stroke. 2006; 37: 351-357
28. Lorenz MW, Karbstein P, Markus HS, et al. High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study. Stroke. 2007; 38: 1774-1779.
29. Falk E, Shah PK, Fuster V,. Coronary plaque disruption. Circulation. 1995; 92: 657-671.
30. Li L, Roumeliotis N, Sawamura T, Renier G,. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res. 2004; 95: 877-883.
31. Bisoendial RJ, Kastelein JJ, Peters SL, et al. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res. 2007; 48: 952-960.
32. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001; 103: 934-940.
33. Yokoya K, Takatsu H, Suzuki T, et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: A study based on four serial coronary arteriograms per year. Circulation. 1999; 100: 903-909.
34. Flugelman MY, Virmani R, Correa R, et al. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina: a clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation. 1993; 88: 2493-2500.
35. Reilly MP, Burnett MS, Epstein SE, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011; 377: 383-392.
36. Nicholls SJ, Wolski K, Sipahi I, et al. Rate of progression of coronary atherosclerotic plaque in women. J Am Coll Cardiol. 2007; 49: 1546-1551.